PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma

Asha Kandathil; Rathan M. Subramaniam

doi:10.1016/j.cpet.2017.05.005

PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma

Asha Kandathil, Rathan M. Subramaniam

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Skeletal and soft tissue sarcomas need early and accurate diagnosis, staging, and treatment for optimal outcome. ¹⁸F-FDG PET/computed tomography (CT) is indicated in staging of patients with high-grade sarcomas and acts as a surrogate marker of histopathologic grade, guiding biopsy to most aggressive portion of the tumor. Pretherapy and posttherapy ¹⁸F-FDG PET/CT metabolic parameters are reliable indicators of survival in patients with sarcoma with an important role in posttreatment response assessment, enabling the treatment plan to be modified in nonresponders. ¹⁸F-FDG PET/CT is particularly useful in the evaluation of molecular targeted therapies, which induce metabolic change before structural change.

Original language	English (US)
Pages (from-to)	475-488
Number of pages	14
Journal	PET Clinics
Volume	12
Issue number	4
DOIs	https://doi.org/10.1016/j.cpet.2017.05.005
State	Published - Oct 2017

Keywords

Molecular targeted therapy
PET
PET/CT
Skeletal sarcoma
Soft tissue sarcoma

ASJC Scopus subject areas

Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.cpet.2017.05.005

Cite this

@article{dc0054c849dc4eb0a8b589f95af37fc2,

title = "PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma",

abstract = "Skeletal and soft tissue sarcomas need early and accurate diagnosis, staging, and treatment for optimal outcome. 18F-FDG PET/computed tomography (CT) is indicated in staging of patients with high-grade sarcomas and acts as a surrogate marker of histopathologic grade, guiding biopsy to most aggressive portion of the tumor. Pretherapy and posttherapy 18F-FDG PET/CT metabolic parameters are reliable indicators of survival in patients with sarcoma with an important role in posttreatment response assessment, enabling the treatment plan to be modified in nonresponders. 18F-FDG PET/CT is particularly useful in the evaluation of molecular targeted therapies, which induce metabolic change before structural change.",

keywords = "Molecular targeted therapy, PET, PET/CT, Skeletal sarcoma, Soft tissue sarcoma",

author = "Asha Kandathil and Subramaniam, {Rathan M.}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = oct,

doi = "10.1016/j.cpet.2017.05.005",

language = "English (US)",

volume = "12",

pages = "475--488",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - PET/Computed Tomography and Precision Medicine

T2 - Musculoskeletal Sarcoma

AU - Kandathil, Asha

AU - Subramaniam, Rathan M.

PY - 2017/10

Y1 - 2017/10

N2 - Skeletal and soft tissue sarcomas need early and accurate diagnosis, staging, and treatment for optimal outcome. 18F-FDG PET/computed tomography (CT) is indicated in staging of patients with high-grade sarcomas and acts as a surrogate marker of histopathologic grade, guiding biopsy to most aggressive portion of the tumor. Pretherapy and posttherapy 18F-FDG PET/CT metabolic parameters are reliable indicators of survival in patients with sarcoma with an important role in posttreatment response assessment, enabling the treatment plan to be modified in nonresponders. 18F-FDG PET/CT is particularly useful in the evaluation of molecular targeted therapies, which induce metabolic change before structural change.

AB - Skeletal and soft tissue sarcomas need early and accurate diagnosis, staging, and treatment for optimal outcome. 18F-FDG PET/computed tomography (CT) is indicated in staging of patients with high-grade sarcomas and acts as a surrogate marker of histopathologic grade, guiding biopsy to most aggressive portion of the tumor. Pretherapy and posttherapy 18F-FDG PET/CT metabolic parameters are reliable indicators of survival in patients with sarcoma with an important role in posttreatment response assessment, enabling the treatment plan to be modified in nonresponders. 18F-FDG PET/CT is particularly useful in the evaluation of molecular targeted therapies, which induce metabolic change before structural change.

KW - Molecular targeted therapy

KW - PET

KW - PET/CT

KW - Skeletal sarcoma

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85026293629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026293629&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2017.05.005

DO - 10.1016/j.cpet.2017.05.005

M3 - Review article

C2 - 28867117

AN - SCOPUS:85026293629

SN - 1556-8598

VL - 12

SP - 475

EP - 488

JO - PET Clinics

JF - PET Clinics

IS - 4

ER -

PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this